4,112
Participants
Start Date
July 31, 2007
Primary Completion Date
December 31, 2009
Study Completion Date
December 31, 2009
amodiaquine-artesunate (ASAQ)
A fix-dose combination tablet containing artesunate-amodiaquine in three different dosages, to be used according to patient age and weight: 25mg/67.5mg; 50mg/135mg; 100mg/270mg
dihydroartemisinin-piperaquine (DHAPQ)
DHAPQ tablets contain either 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.
artemether-lumefantrine (AL)
Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine.
Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)
"Lapdap tablets contain 15/18.75mg or 80/100mg of Chlorproguanil Hydrochloride and Dapsone, respectively. Arsumax® tablets contain 50mg Artesunate.~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008."
Centre Muraz/IRSS, Bobo-Dioulasso
Albert Schweitzer Hospital, Lambaréné
Manhiça Health Research Center, Manhiça
Hospital, Calabar
Mashshesha and Rukara, Kigali
Jinja and Tororo, Kampala
Mbarara,, Mbarara
Tropical Diseases Research Centre, P O Box 71769,, Ndola
Liverpool School of Tropical Medicine
OTHER
East African Network for Monitoring Antimalarial Treatment
NETWORK
Centre Muraz
OTHER
University of Calabar
OTHER
Tropical Diseases Research Centre, Zambia
OTHER_GOV
University Hospital Tuebingen
OTHER
Albert Schweitzer Hospital
OTHER
Uganda Malaria Surveillance Project
OTHER
Mbarara University of Science and Technology
OTHER
Ministry of Health, Rwanda
OTHER_GOV
University of Barcelona
OTHER
Centro de Investigacao em Saude de Manhica
OTHER
Institute of Tropical Medicine, Belgium
OTHER